Skip to main content

Table 1 Demographics and disease characteristics by country

From: Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire

 Global totalAustraliaBrazilCanadaFranceSpainTaiwanUKUS
Unweighted Base, N1286152152155123135109159301
Weighted Base, N128639319621118541109521
Age, years, mean (SD)41.2 (13.3)45.7 (13.7)33.4 (8.9)49.1 (15.4)40.9 (12.6)36.9 (9.1)43.3 (10.4)41.5 (11.5)45.1 (14.2)
Female, n (%)674 (52)16 (41)151 (47)32 (52)49 (44)35 (41)17 (40)56 (52)318 (61)
Current overall health, n (%)a
 Excellent57 (4)1 (2)4 (1)3 (5)3 (2)1 (1)2 (4)2 (2)42 (8)
 Good388 (30)10 (27)94 (30)27 (45)13 (12)5 (6)6 (15)19 (17)213 (41)
 Fair674 (52)21 (55)187 (59)26 (42)74 (67)42 (50)26 (63)67 (61)232 (45)
 Poor167 (13)6 (16)34 (11)5 (8)21 (19)37 (44)8 (18)22 (20)35 (7)
Time since diagnosis of PsA, years, mean (SD)9.0 (8.6)8.5 (8.2)7.2 (6.0)12.3 (11.4)8.5 (6.3)8.8 (7.2)6.2 (5.0)8.1 (6.3)10.3 (10.5)
Current PsA disease severity, n (%)b
 Mild205 (16)11 (28)50 (16)22 (35)12 (11)13 (15)17 (40)22 (20)59 (11)
 Moderate849 (66)24 (61)243 (76)32 (52)75 (67)67 (79)21 (51)73 (67)315 (60)
 Severe232 (18)4 (11)25 (8)8 (12)24 (22)6 (7)3 (8)14 (13)147 (28)
Current PsA medication, n (%)
 bDMARD only483 (38)7 (19)78 (24)23 (38)50 (46)20 (24)9 (22)25 (23)270 (52)
 Oral DMARD only419 (33)14 (36)120 (37)18 (30)31 (28)41 (49)20 (49)45 (42)130 (25)
 Oral DMARD + bDMARD228 (18)6 (16)80 (25)11 (17)13 (11)14 (17)9 (23)15 (14)80 (15)
 NSAIDs/steroids only140 (11)10 (27)42 (13)8 (13)14 (13)8 (10)3 (6)23 (21)31 (6)
 Not sure6 (< 0.5)< 0.5 (1)0 (0)1 (1)3 (2)1 (1)0 (0)0 (0)2 (< 0.5)
 Not currently taking PsA medication10 (1)1 (1)0 (0)< 0.5 (1)0 (0)0 (0)0 (0)0 (0)9 (2)
  1. Raw data were not weighted at the individual country level, and are therefore only representative of the individuals who completed the survey. For the global, eight-country total, a post-weight was applied to adjust for the relative size of each country’s adult population within the total adult population across all countries surveyed. The unweighted sample sizes reflect the total number of patients who completed the survey, while all reported percentages are calculated based on the weighted global total as the denominator. Percentages might not exactly match those derived by manual calculation due to weighting and/or computer rounding
  2. bDMARD Biologic disease-modifying antirheumatic drug, NSAID Non-steroidal anti-inflammatory drug, PsA Psoriatic arthritis, SD Standard deviation
  3. aPatients were asked, “How would you describe your current overall health today?” and gave subjective answers of either “excellent”, “good”, “fair”, or “poor”, without formal definition of the designations
  4. bPatients were asked, “How bad is your psoriatic arthritis today?” and gave subjective answers of either “mild”, “moderate”, or “severe”, without formal definition of the designations